Neoadjuvant therapy for gastrointestinal stromal tumor

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Molecular-targeting therapy with imatinib mesylate is effective for metastatic/recurrent gastrointestinal stromal tumors (GISTs).
• Imatinib is a potential neoadjuvant therapy for high-risk GIST, aiming to shrink tumors before surgery.

Purpose of the Study:

• To review existing evidence and strategies for neoadjuvant imatinib therapy in GIST.
• To explore the potential benefits of neoadjuvant therapy, including increased resection rates and organ preservation.

Main Methods:

• Review of existing clinical trial data and literature on neoadjuvant imatinib therapy for GIST.
• Analysis of strategies and evidence regarding tumor shrinkage and its impact on surgical outcomes.

Main Results:

• Clinical trials have established the feasibility of neoadjuvant imatinib therapy.
• Neoadjuvant therapy may increase complete resection rates and avoid surgical rupture by reducing tumor size.
• Potential benefits include improved recurrence and survival rates, along with organ/function preservation.

Conclusions:

• Neoadjuvant imatinib therapy is feasible for high-risk GIST.
• While promising for improving surgical outcomes and potentially survival, definitive proof of survival effectiveness requires further demonstration.
• Further research is warranted to solidify the role of neoadjuvant imatinib in GIST management.